Search

everythinglearnresearchcommunity

for

Search:↓

Skin disease activity scores can help decide when skin symptoms no longer affect the quality of life in patients with mild dermatomyositis.

The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.

Cannabinoids like CBD and THC may help treat non-cancer skin diseases, but more research is needed.

Watching, not removing, skin growths with moderate atypia and positive edges is okay; patients may get melanoma elsewhere, especially if they've had it before.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

Psoriasis patients are willing to pay less than the cost of biologic treatments for remission and don't expect complete or long-term symptom clearance.

The conclusion is that differentiating wound types in RDEB patients is important for clinical trials and understanding the disease.

Platelet Rich Plasma can potentially help in restoring hair loss, but more research with larger groups is needed to confirm its effectiveness and standardize its use.

The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.

Hydroxychloroquine may cause false results in tuberculosis tests for patients with autoimmune skin diseases.

Cannabinoids may help some skin conditions but more research is needed.

CLASI is a valid tool for assessing skin activity and damage in lupus patients.

The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.

The document concludes that recognizing and treating cutaneous lupus erythematosus early is crucial for managing the skin and potential systemic symptoms.

Most patients with cutaneous dermatomyositis either improved or remained stable over 3.5 years.

Skin problems are common in Lupus patients and can indicate the disease's severity, requiring specific treatments and lifestyle changes.

Skin problems are common in lupus patients and should be treated early to prevent worsening.

Skin problems are common in lupus, often appearing first, with various types and treatments, and careful monitoring is important for diagnosis and management.

Lupus is a complex disease that requires personalized treatment because it varies greatly between individuals.

Type I interferons play a key role in the development of various skin diseases.

Apremilast shows promise for several skin conditions but needs more research.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

Lupus can cause different skin problems, and treatments like quitting smoking and using certain creams or medicines can help.

Psoriasis patients experience moderate functional impairment related to disease severity and less satisfaction.

Patients with Discoid Lupus Erythematosus have lower vitamin D and antioxidant levels and higher oxidative stress.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.

Patients with cutaneous lupus erythematosus have a severely impaired quality of life, especially emotionally.

Psoriasis is linked to other autoimmune diseases and involves a specific inflammatory process.

Effective treatment for hidradenitis suppurativa varies, with antibiotics commonly used and surgery as an option, but no single method is universally successful.